Corvus Pharmaceuticals CRVS Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's accounts payable?
- Corvus Pharmaceuticals (CRVS) reported accounts payable of $4.7M in Q1 2026.
- How has Corvus Pharmaceuticals's accounts payable changed year-over-year?
- Corvus Pharmaceuticals's accounts payable increased by 259.1% year-over-year, from $1.31M to $4.7M.
- What is the long-term trend for Corvus Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's accounts payable has grown at a -6.4% compound annual growth rate (CAGR), from $3.47M to $2.49M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.